Caris Life Sciences to Attend Q4 2025 Investor Conferences

Caris Life Sciences to Attend Q4 2025 Investor Conferences News provided by Caris Life Sciences Nov 17, 2025, 08:30 ET Share this article Share to X Share this article Share to X IRVING, Texas , Nov. 17, 2025 /PRNewswire/ -- Caris Life Sciences ® (NASDAQ: CAI ), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced that the company will attend the following investor conferences: Wolfe Research's 7th Annual Healthcare Conference: New York City, New York Investor meetings: November 18 Citi's 2025 Global Healthcare Conference: Miami, Florida Investor meetings: December 3 8 th Annual Evercore Healthcare Conference: Miami, Florida Investor meetings: December 4 Contact [email protected] to schedule meetings. About Caris Life Sciences Caris Life Sciences® (Caris) is a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer that is actively developing and commercializing innovative solutions to transform healthcare. Through comprehensive molecular profiling (Whole Exome and Whole Transcriptome Sequencing) and the application of advanced AI and machine learning algorithms at scale, Caris has created the large-scale, multimodal clinico-genomic database and computing capability needed to analyze and further unravel the molecular complexity of disease. This convergence of next-generation sequencing, AI and machine learning technologies, and high-performance computing provides a differentiated platform to develop the latest generation of advanced precision medicine diagnostic solutions for early detection, diagnosis, monitoring, therapy selection and drug development. Caris was founded with a vision to realize the potential of precision medicine in order to improve the human condition. Headquartered in Irving, Texas, Caris has offices in Phoenix, New York, Cambridge (MA), Tokyo, Japan and Basel, Switzerland. Caris or its distributor partners provide services in the U.S. and other international markets. Caris Life Sciences Media: Corporate Communications [email protected] 214.294.5606 Investor Relations: [email protected] 917.689.3511 SOURCE Caris Life Sciences 21 % more press release views with Request a Demo × Modal title